EP0341261A1 - Anti-smoking agent - Google Patents

Anti-smoking agent

Info

Publication number
EP0341261A1
EP0341261A1 EP88901252A EP88901252A EP0341261A1 EP 0341261 A1 EP0341261 A1 EP 0341261A1 EP 88901252 A EP88901252 A EP 88901252A EP 88901252 A EP88901252 A EP 88901252A EP 0341261 A1 EP0341261 A1 EP 0341261A1
Authority
EP
European Patent Office
Prior art keywords
family
composition according
smoking
components
cimicifugae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88901252A
Other languages
German (de)
French (fr)
Inventor
Vladimir Dr. Badmajew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0341261A1 publication Critical patent/EP0341261A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/51Gentianaceae (Gentian family)
    • A61K36/515Gentiana
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/888Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888Pinellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Definitions

  • a disadvantage of the known chemical or biochemical agents against smoking are, in particular, their side effects, which occur when the known agents are taken. Furthermore, their effects are not as successful.
  • the intake, in particular the continued intake of the known means presupposes a determined and constant will of the patient, which experience shows that the patient applies during an initial phase of the intake, but often - after a certain weaning time - often no longer applies able. This is especially true when the first withdrawal symptoms occur and side effects, such as. B. weight gain etc. occur. It is at this stage that the willpower of many people wishing to quit waning. At this stage, however, the known biochemicals do not adequately support the person wishing to quit.
  • the invention is therefore based on the object of avoiding the disadvantages of the known biochemical weaning agents and of providing a bio-chemical agent which within a relatively short period of time, for example a few days (two to five days), spoils the person weaning from smoking so that he the therapy also in the following days perseveres.
  • the drug should evoke such a strong aversion to smoking that the person wishing to withdraw it feels physical discomfort, especially nausea, if he smokes after taking the drug or even smokes a smoke as a passive smoker another smoker inhales.
  • the invention aims at a strong anti-nicotine effect. The aim is to achieve an incompatibility between the smoking products and the agent according to the invention.
  • an anti-smoking agent with a bio-chemical effect which is composed of the following, non-toxic plant components:
  • These components can be in any dosage form, e.g. B. as a chewable tablet, normal, oral tablet or as a suitable tea preparation substance.
  • the dosage form is preferred as a chewable tablet.
  • As a chewable tablet however, the very bitter taste comes into full effect, but it can be modified, suppressed or changed by suitable additives (sugar, flavorings or the like).
  • the combination of the components mentioned causes an aversion to smoke and to smoking, which is triggered when a cigarette is lit.
  • This aversion also occurs when you as a passive smoker inhale the smoke of other smokers.
  • a bitter taste is produced in the mouth after taking the pharmaceutical, which initially spoils the enjoyment of smoking.
  • a defense reaction of the central nervous system is brought about. This is attributed to a change in the taste sensation in the brain.
  • the parasymphatic nervous system is stimulated, which in turn triggers nausea, nausea, through which smoke nausea or nausea is increased.
  • the herbal mixture according to the invention strengthens the nerves and the organs of the body.
  • the anti-smoking effect sets in after a few days, for example two to four days. It first makes itself felt in an uncomfortable situation when a cigarette is lit.
  • the herbal ingredients used have a strong antinicotic effect, while smoking a cigarette or passive smoking causes nausea that can lead to vomiting. In terms of taste, there is an incompatibility between the smoking products and the components of the herbal active ingredients.
  • the pharmaceutical according to the invention causes weight loss when ingested. This is a particular advantage, because due to the nicotine, a person who wants to withdraw usually buzzes with weight, in any case with conventional anti-smoking therapies a weight gain is found a few days after the cessation of smoking. This increase in weight is counteracted by the agent according to the invention due to its slimness.
  • the effect of the pharmaceutical according to the invention directed against the enjoyment of smoking is not a psychological but a sensory contrast (incompatibility) that is noticeable both at the local sensory level and in the area of the central brain.
  • the agent has proven to be effective in reducing the enjoyment of drinking coffee. This is attributed in particular to Pinellia ternata. A taste incompatibility with coffee is achieved, a tingling, tingling, biting or burning sensation occurs in the mouth or throat when drinking coffee after taking the agent. When the agent was taken for a long time, it was found in test subjects that daily coffee consumption erroneously. In addition, there are indications that the drug also spoils the use of drugs. Initial, quite preliminary trials have shown that the drug can also be used in other drug and toxic cases Substances have an effect, e.g. B. when smoking marijuana, with excessive alcohol consumption and also in the last stage of a cocaine addiction.
  • Radix bupleuri is the root of the BUPLEURUM falcatum L. from the Umbelliferae family. The herb is native to Southern and Central Europe, East Asia and especially Japan. Its use against fever is well known. The essential chemical components are 0.5% bupleurumol C-.H fi4 0 2 , 2% A-spinasterol and rutin 2 H 3o 0 i6 '
  • Radix peucedani is the root of PEUCEDANUM praeruptorum thin, also from the Umbelliferae family. Its use in gastric medicine and skin diseases is known.
  • the root contains, among other things, essential oils and bitter substances, in particular nodakenin C 20 H 24 ° 9 'sponsterol and nodakenetin C, .H, .0 ..
  • Rhizoma cimicifugae is the root of the CIMICIFUGAE foetida L. from the Ranunculaceae family. The plant is native to North America and has the active ingredient ⁇ Cimitin C 2Q H., .0-, and Cimicifugih.
  • Rhiz ⁇ na phragmites are the root and stem of PHRAGMUES ar-itunis L. Trinius of the family of the Gramineae, the German name is reed. Up to 77% silica is found in the ashes. Rhizoma Phragmites has a sweet taste, the medicinal effect extends to the lungs, stomach and liver. Some protein, fat and carbohydrates are found in the chemical composition.
  • the root of the Liquiritiae or Glycyrrhize contains steroid-like hormones which are said to have an anti-inflammatory effect.
  • the root contains the intensely sweet-tasting one Triterpensaponin Glycyrrhizinklare, which forms a gelatin-like mixture with water, which forms a protective coating in the neck area.
  • the licorice root Radix glycyrrhize gives the agent a pleasant taste.
  • Essential ingredients are 10% glycyrrhizin, potassium, 12% terpenoid saponins, e.g. B. as the already mentioned Glycyrrhizin ⁇ acid, liquiritin, isoliquiritin (flavonoids), 1 to 2% asparagine and 6% glycymarin (bitter taste).
  • Pinellia ternata from the Araceae family has pinelin, starch and volatile oils as active ingredients.
  • the vegetable components are present in the following weight percentages:
  • Example 1 Radix bupleuri 25%, Radix peucedani 20%, Rhiz ⁇ na cimicifugae 25%, Tubera pinelliae 20% and Rhizcma phragmites 10%.
  • the starting point is fully dosed (saturated) aqueous solutions of Radix bupleuri 3-5 g, Radix peucedani 5-10 g, Rhiz ⁇ na cimicifugae 3-5 g, Tubera pinelliae 5-10 g and Rhizcma phragmites 15-30 g.
  • Example 2 Peucedanum praeruptorum from the Ranunculaceae family 30%, Gentiana barbata from the Gentianaciae family 24%, Cimicifugae foetida from the Ranunculaceae family 12%, Liquiritiae from the Leguminosae family or Robiniae pseudoacaciae 4 from the Leguminosae family %, Bupleurum falcatum from the Umbelliferae family 12% and Pinellia ternata from the Araceae family 18%
  • the plant constituents are simply mixed together during production; it is possible, but not necessary, to use special binders.
  • a gum material for example chicle gurriii, polyvinyl ester or polyethylene, is used in the manufacture of chewable tablets, that is to say materials such as are also used for the production of chewing gums.
  • Sugar obtained from honey is preferably added.
  • the chewable tablet formulation has a very long-lasting effect; the individual active ingredients are stig and open to the longer chewing time and therefore develop their effect to the desired extent.
  • a tea can also be prepared instead.
  • the preparation takes place like with a tea preparation with normal tea leaves. Hot water is poured into a cup over at least one tablet of the pha ____ a.zeut__kums according to the invention, the preparation is allowed to stand for a few minutes and is drunk while it is still hot.
  • the treatment should be continued until an effect is felt, but should not be given for more than five days. If after this time no effect, i.e. no aversion to smoking and smoking, is found, it is recommended to pause for two to three days and then to start a five-day course again.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Un agent anti-tabagique possédant une action biochimique se compose des ingrédients végétaux suivants: radix bupleuri, radix peucedani, rhizoma cimicifugae et tubera pinelliae.An anti-smoking agent with biochemical action consists of the following plant ingredients: radix bupleuri, radix peucedani, rhizoma cimicifugae and tubera pinelliae.

Description

Bezeichnung: Mittel gegen das Rauchen Name: Remedy for smoking
Die Erfindung bezieht sich auf ein Mittel gegen das Rauchen mit bioche mischer Wirkung.The invention relates to an anti-smoking agent with a biochemical effect.
Die mit dem Rauchen verbundenen und durch das Rauchen hervorgerufenen gesundheitlichen Nachteile werden irrmer stärker beachtet. Es ist zwi¬ schenzeitlich auch allgemein bekannt geworden, daß auch Nichtraucher, die in Gesellschaft von Rauchern durch den Rauch zu Passivrauchern werden, auf die Dauer schädliche Auswirkungen für ihre Gesundheit befürchten müssen. Daher ist es bereits seit langem versucht worden, Verfahren oder Mitt^1. unterschiedlicher Art anzugeben, die allesamt das Ziel haben, gegen das Rauchen zu wirken, indem sie dem Rauchenden den Rauchgenuß verleiden, ihn psychologisch gegen das Rauchen motivieren, den Rauchgenuß auf andere leibliche Genüsse verlagern oder dergleichen.The health-related disadvantages associated with smoking and caused by smoking are given even more attention. In the meantime, it has also become generally known that even non-smokers who, in the company of smokers, become smoke through the smoke become passive smokers, have to fear harmful effects on their health in the long run. Therefore, it has long been tried, procedure or Mitt ^ 1 . to indicate different types, all of which aim to act against smoking by denying smoking to the smoker, motivating him psychologically against smoking, shifting the smoking pleasure to other physical pleasures or the like.
Nachteilig bei den bekannten chemischen oder biochemischen Mitteln gegen das Rauchen sind insbesondere deren Nebenwirkungen, die sich bei der Einnahme der vorbekannten Mittel einstellen. Weiterhin ist ihre Wirkung nicht irrmer erfolgreich. Die Einnahme, insbesondere die fortge¬ setzte Einnahme der vorbekannten Mittel setzt einen entschiedenen und konstant durchgehaltenen Willen des Patienten voraus, den dieser erfah¬ rungsgemäß innerhalb einer Anfangsphase der Einnahme aufbringt, später aber - nach einer gewissen Entwöhnungszeit - oftmals nicht mehr aufzu¬ bringen in der Lage ist. Dies insbesondere, wenn sich die ersten Ent¬ zugserscheinungen einstellen und Nebenwirkungen, wie z. B. Gewichtszu¬ nahme u.s.w., auftreten. Gerade in diesem Stadium erlahmt die Willens¬ kraft vieler Entwöhnungswilliger. In diesem Stadium aber unterstützen die vorbekannten biochemischen Mittel den Entwöhnungswilligen nicht ausreichend.A disadvantage of the known chemical or biochemical agents against smoking are, in particular, their side effects, which occur when the known agents are taken. Furthermore, their effects are not as successful. The intake, in particular the continued intake of the known means, presupposes a determined and constant will of the patient, which experience shows that the patient applies during an initial phase of the intake, but often - after a certain weaning time - often no longer applies able. This is especially true when the first withdrawal symptoms occur and side effects, such as. B. weight gain etc. occur. It is at this stage that the willpower of many people wishing to quit waning. At this stage, however, the known biochemicals do not adequately support the person wishing to quit.
Der Erfindung liegt daher die Aufgabe zugrunde, die Nachteile der vorbekannten biochemischen Entwöhnungsmittel zu vermeiden und ein bio¬ chemisches Mittel anzugeben, das innerhalb relativ kurzer Zeit, bei¬ spielsweise wenigen Tagen (zwei bis fünf Tage) dem Entwöhnungswilligen das Rauchen so verleidet, daß er die Therapie auch in den Folgetagen durchhält. Dabei soll das Mittel innerhalb der ersten Tage der Einnahme eine so starke Aversion gegen das Rauchen beim Entzugswilligen hervor¬ rufen, daß dieser ein körperliches Unwohlsein, insbesondere Übelkeit, empfindet, wenn er nach Einnahme des Mittels raucht oder gar als Pas¬ sivraucher den Rauch eines anderen Rauchers einatmet. Die Erfindung zielt dabei auf einen starken Antinikotineffekt ab. Es soll eine e - pfindungsmäßige Unverträglichkeit zwischen den Rauchprodukten und dem erfindungsgemäßen Mittel erreicht werden.The invention is therefore based on the object of avoiding the disadvantages of the known biochemical weaning agents and of providing a bio-chemical agent which within a relatively short period of time, for example a few days (two to five days), spoils the person weaning from smoking so that he the therapy also in the following days perseveres. During the first few days of taking the drug, the drug should evoke such a strong aversion to smoking that the person wishing to withdraw it feels physical discomfort, especially nausea, if he smokes after taking the drug or even smokes a smoke as a passive smoker another smoker inhales. The invention aims at a strong anti-nicotine effect. The aim is to achieve an incompatibility between the smoking products and the agent according to the invention.
Diese Aufgabe wird gelöst durch ein Mittel gegen das Rauchen mit bio¬ chemischer Wirkung, das aus den folgenden, nicht giftigen pflanzlichen Bestandteilen zusammengesetzt ist:This object is achieved by an anti-smoking agent with a bio-chemical effect, which is composed of the following, non-toxic plant components:
RADIX BUPLEURI, RADIX PEUCEDANI, RHIZQMA CIMICIFUGAE und TUBERA PINELLIAE. Diesen Bestandteilen kann entweder Rhizcma phragmites oder eine Mischung aus Pinellia ternata und Liquiritiae, wobei Liquiritiae durch Robiniae pseudoacaciae ersetzt werden kann, zugefügt werden.RADIX BUPLEURI, RADIX PEUCEDANI, RHIZQMA CIMICIFUGAE and TUBERA PINELLIAE. Either Rhizcma phragmites or a mixture of Pinellia ternata and Liquiritiae can be added to these components, whereby Liquiritiae can be replaced by Robiniae pseudoacaciae.
Diese -Bestandteile können in beliebiger Darreichungsform, z. B. als Kautablette, normale, oral einzunehmende Tablette oder als für eine Teezubereitung geeignete Substanz hergestellt werden. Bevorzugt wird die Darreichungsform als Kautablette. Als Kautablette kommt der sehr bittere Geschmack allerdings voll zur Wirkung, er kann jedoch durch geeignete Zusätze (Zucker, Aromastoffe oder dergleichen) abgewandelt, übeι±ιrückt oder verändert werden.These components can be in any dosage form, e.g. B. as a chewable tablet, normal, oral tablet or as a suitable tea preparation substance. The dosage form is preferred as a chewable tablet. As a chewable tablet, however, the very bitter taste comes into full effect, but it can be modified, suppressed or changed by suitable additives (sugar, flavorings or the like).
Durch die Kombination der genannten Bestandteile wird eine Aversion gegen Rauch und gegen Rauchen hervorgerufen , die schon dann ausgelöst wird, wenn eine Zigarette angezündet wird. Diese Aversion tritt auch auf, wenn man als Passivraucher den Rauch anderer Raucher einatmet. Beim aktiven oder passiven Rauchen wird nach Einnahme des Pharmazeuti- kums ein bitterer Geschmack im Mund hervorgerufen, der den Rauchgenuß zunächst verleidet. Darüberhinaus und als zusätzliche Wirkung wird eine Abwehrreaktion des zentralen Nervensystems bewirkt. Diese wird auf eine Änderung des Geschmacksempfindens im Gehirn zurückgeführt. Weiterhin wird das parasymphatische Nervensystem stimuliert, das seinerseits Übelkeit, Brechreiz auslöst, durch die beim Einatmen von Rauch gerin- gere Sauerstoffmenge wird die Übelkeit bzw. der Brechreiz potenziert. Die erfindungsgemäße Kräutermischung stärkt die Nerven und die Körper organe. Der Anti-Raucheffekt stellt sich nach wenigen Tagen, beispiel weise zwei bis vier Tagen, ein. Er macht sich zunächst in einem Unwoh sein bemerkbar, wenn eine Zigarette angezündet wird.The combination of the components mentioned causes an aversion to smoke and to smoking, which is triggered when a cigarette is lit. This aversion also occurs when you as a passive smoker inhale the smoke of other smokers. In active or passive smoking, a bitter taste is produced in the mouth after taking the pharmaceutical, which initially spoils the enjoyment of smoking. In addition and as an additional effect, a defense reaction of the central nervous system is brought about. This is attributed to a change in the taste sensation in the brain. Furthermore, the parasymphatic nervous system is stimulated, which in turn triggers nausea, nausea, through which smoke nausea or nausea is increased. The herbal mixture according to the invention strengthens the nerves and the organs of the body. The anti-smoking effect sets in after a few days, for example two to four days. It first makes itself felt in an uncomfortable situation when a cigarette is lit.
Die benutzten pflanzlichen Bestandteile haben einen starken Antiniko- tineffekt, beim Rauchen einer Zigarette oder beim passiven Rauchen wi eine Übelkeit hervorgerufen, die bis zum Zwang von Erbrechen gehen kann. Geschmacksmäßig tritt eine Unverträglichkeit auf zwischen den Rauchprodukten und den Bestandteilen der pflanzlichen Wirkstoffe.The herbal ingredients used have a strong antinicotic effect, while smoking a cigarette or passive smoking causes nausea that can lead to vomiting. In terms of taste, there is an incompatibility between the smoking products and the components of the herbal active ingredients.
Das erfindungsgemäße Pharmazeutikum bewirkt bei Einnahme eine Gewichts abnahme. Dies ist ein besonderer Vorteil, denn aufgrund des Nikotinent zuges nirrmt ein Entzugswilliger normalerweise an Gewicht zu, jedenfall wird bei üblichen Anti-Raucher-Therapien eine Gewichtszunahme wenige Tage nach dem Einstellen des Rauchens festgestellt. Dieser Gewichtszu¬ nahme wirkt das erfindungsgemäße Mittel aufgrund seiner schlank machen den Wirkung entgegen.The pharmaceutical according to the invention causes weight loss when ingested. This is a particular advantage, because due to the nicotine, a person who wants to withdraw usually buzzes with weight, in any case with conventional anti-smoking therapies a weight gain is found a few days after the cessation of smoking. This increase in weight is counteracted by the agent according to the invention due to its slimness.
Insgesamt ist die gegen den Rauchgenuß gerichtete Wirkung des erfin- dungsgeϊräßen Pharmazeutikums keine psychologische, sondern eine senso¬ rische Gegensätzlichkeit (Unverträglichkeit) die sich sowohl auf loka¬ lem sensorischem Niveau, als auch im Bereich des Zentralhirns bemerkba macht.Overall, the effect of the pharmaceutical according to the invention directed against the enjoyment of smoking is not a psychological but a sensory contrast (incompatibility) that is noticeable both at the local sensory level and in the area of the central brain.
Darüberhinaus hat sich das Mittel als wirksam dahingehend erwiesen, de Genuß beim Kaffeetrinken zu verleiden. Dies wird insbesondere auf Pinellia ternata zurückgeführt. Es wird eine Geschmacksunverträglich¬ keit mit Kaffee erreicht, ein Prickeln, Kribbeln, Beißen oder Brennen tritt in Mund oder Rachen auf, wenn nach Einnahme des Mittels Kaffee getrunken wird. Bei längerer Einnahme des Mittels wurde bei Testperso¬ nen festgestellt, daß der tägliche Kaffeekonsum abnirrmt. Zusätzlich liegen Hinweise dafür vor, daß das Mittel auch den Genuß von Drogen verleidet. Erste, recht vorläufige Versuche haben gezeigt, daß das Mittel auch in anderen Fällen der Einnahme von Drogen und toxischen Substanzen eine Wirkung zeigt,, z. B. bei Rauchen von Marihuana, bei übermäßiger Alkoholeinnahme und auch im letzten Stadium einer Kokain- Abhängigkeit.In addition, the agent has proven to be effective in reducing the enjoyment of drinking coffee. This is attributed in particular to Pinellia ternata. A taste incompatibility with coffee is achieved, a tingling, tingling, biting or burning sensation occurs in the mouth or throat when drinking coffee after taking the agent. When the agent was taken for a long time, it was found in test subjects that daily coffee consumption erroneously. In addition, there are indications that the drug also spoils the use of drugs. Initial, quite preliminary trials have shown that the drug can also be used in other drug and toxic cases Substances have an effect, e.g. B. when smoking marijuana, with excessive alcohol consumption and also in the last stage of a cocaine addiction.
Radix bupleuri ist die Wurzel des BUPLEURUM falcatum L. aus der Familie der Umbelliferae. Das Kraut ist in Süd- und Mitteleuropa, Ostasien und insbesondere in Japan heimisch. Seine Verwendung gegen Fieber ist bekannt. Wesentliche chemische Bestandteile sind 0,5 % Bupleurumol C-.Hfi402, 2 % A-Spinasterol und Rutin 2 H3o0i6' Radix bupleuri is the root of the BUPLEURUM falcatum L. from the Umbelliferae family. The herb is native to Southern and Central Europe, East Asia and especially Japan. Its use against fever is well known. The essential chemical components are 0.5% bupleurumol C-.H fi4 0 2 , 2% A-spinasterol and rutin 2 H 3o 0 i6 '
Radix peucedani ist die Wurzel des PEUCEDANUM praeruptorum Dünn, eben¬ falls aus der Familie der Umbelliferae. Seine Verwendung in der Magen¬ heilkunde und bei Hautkrankheiten ist bekannt. Die Wurzel enthält u. a. ätherische Öle und Bitterstoffe, insbesondere Nodakenin C20H24°9' Sponsterol und Nodakenetin C,.H, .0..Radix peucedani is the root of PEUCEDANUM praeruptorum thin, also from the Umbelliferae family. Its use in gastric medicine and skin diseases is known. The root contains, among other things, essential oils and bitter substances, in particular nodakenin C 20 H 24 ° 9 'sponsterol and nodakenetin C, .H, .0 ..
Rhizoma cimicifugae ist die Wurzel des CIMICIFUGAE foetida L. aus der Familie der Ranunculaceae. Die Pflanze ist in Nordamerika heimisch und hat die Wirkbestandteil<^ Cimitin C2QH., .0-, und Cimicifugih.Rhizoma cimicifugae is the root of the CIMICIFUGAE foetida L. from the Ranunculaceae family. The plant is native to North America and has the active ingredient <^ Cimitin C 2Q H., .0-, and Cimicifugih.
Tubera pinelliae ist die Knolle, Wurzel oder der Stamm der PINELLIA ternata Breitenbach (P. tuberiferarum triphyllum aus der Familie der Araceae) . Die Pflanze ist in Ostasien heimisch. Die chemische Zusammen¬ setzung weist u. a. 0,003 bis 0,13 % flüchtige Öle, einige Alkaloide, Fettöle und Stärke auf, beispielsweise Pinelin.Tubera pinelliae is the tuber, root or stem of the PINELLIA ternata Breitenbach (P. tuberiferarum triphyllum from the Araceae family). The plant is native to East Asia. The chemical composition shows u. a. 0.003 to 0.13% volatile oils, some alkaloids, fatty oils and starch, for example pinelin.
Rhizαna phragmites sind die Wurzel und der Stamm der PHRAGMUES ar-itunis L. Trinius der Familie der Gramineae, die deutsche Bezeichnung ist Schilfrohr. In der Asche findet man bis zu 77 % Kieselsäure. Rhizoma Phragmites ist süßlich im Geschmack, die medizinische Wirkung erstreckt sich auf Lungen, Magen und Leber. In der chemischen Zusammen¬ setzung findet man etwas Protein, Fett und Carbohydrate.Rhizαna phragmites are the root and stem of PHRAGMUES ar-itunis L. Trinius of the family of the Gramineae, the German name is reed. Up to 77% silica is found in the ashes. Rhizoma Phragmites has a sweet taste, the medicinal effect extends to the lungs, stomach and liver. Some protein, fat and carbohydrates are found in the chemical composition.
Die Wurzel der Liquiritiae bzw. Glycyrrhize enthält stereoid- hnliche Hormone, denen eine entzündungsmildernde Wirkung zugeschrieben wird. Als Hauptwirkstoff enthält die Wurzel das intensiv süß schmeckende Triterpensaponin Glycyrrhizinsäure, die eine gelantineartige Mischung mit Wasser bildet, die im Halsbereich einen schützenden Überzug bildet. Die Süßholzwurzel Radix glycyrrhize verleiht dem Mittel einen angeneh¬ men Geschmack. Wesentliche Bestandteile sind 10 % Glycyrrhizin, Kalium, 12 % Terpenoid-saponine, z. B. wie die bereits erwähnte Glycyrrhizin¬ säure, Liquiritin, Isoliquiritin (Flavonoide) , 1 bis 2 % Asparagin und 6 % Glycymarin (bitterer Geschmack) .The root of the Liquiritiae or Glycyrrhize contains steroid-like hormones which are said to have an anti-inflammatory effect. As the main active ingredient, the root contains the intensely sweet-tasting one Triterpensaponin Glycyrrhizinsäure, which forms a gelatin-like mixture with water, which forms a protective coating in the neck area. The licorice root Radix glycyrrhize gives the agent a pleasant taste. Essential ingredients are 10% glycyrrhizin, potassium, 12% terpenoid saponins, e.g. B. as the already mentioned Glycyrrhizin¬ acid, liquiritin, isoliquiritin (flavonoids), 1 to 2% asparagine and 6% glycymarin (bitter taste).
Pinellia ternata aus der Familie Araceae hat als Wirkstoffe Pinelin, Stärke und flüchtige Öle.Pinellia ternata from the Araceae family has pinelin, starch and volatile oils as active ingredients.
In bevorzugter Weiterbildung der Erfindung wird vorgeschlagen, daß die pflanzlichen Bestandteile in folgenden Gewichtsprozenten vorliegen:In a preferred further development of the invention, it is proposed that the vegetable components are present in the following weight percentages:
(Beispiel 1) : Radix bupleuri 25 %, Radix peucedani 20 %, Rhizαna cimicifugae 25 %, Tubera pinelliae 20 % und Rhizcma phragmites 10 %. Ausgegangen wird dabei von volldosierten (gesättigten) wässrigen Lö¬ sungen von Radix bupleuri 3 - 5 g, Radix peucedani 5 - 10 g, Rhizαna cimicifugae 3 - 5 g, Tubera pinelliae 5 - 10 g und Rhizcma phragmites 15 - 30 g.(Example 1): Radix bupleuri 25%, Radix peucedani 20%, Rhizαna cimicifugae 25%, Tubera pinelliae 20% and Rhizcma phragmites 10%. The starting point is fully dosed (saturated) aqueous solutions of Radix bupleuri 3-5 g, Radix peucedani 5-10 g, Rhizαna cimicifugae 3-5 g, Tubera pinelliae 5-10 g and Rhizcma phragmites 15-30 g.
(Beispiel 2) : Peucedanum praeruptorum aus der Familie der Ranunculaceae 30 %, Gentiana barbata aus der Familie der Gentianaciae 24 %, Cimicifugae foetida aus der Familie der Ranunculaceae 12 %, Liquiritiae aus der Familie der Leguminosae oder Robiniae pseudoacaciae aus der Familie der Leguminosae 4 %, Bupleurum falcatum aus der Familie der Umbelliferae 12 % und Pinellia ternata aus der Familie der Araceae 18 %(Example 2): Peucedanum praeruptorum from the Ranunculaceae family 30%, Gentiana barbata from the Gentianaciae family 24%, Cimicifugae foetida from the Ranunculaceae family 12%, Liquiritiae from the Leguminosae family or Robiniae pseudoacaciae 4 from the Leguminosae family %, Bupleurum falcatum from the Umbelliferae family 12% and Pinellia ternata from the Araceae family 18%
Bei der Herstellung werden die pflanzlichen Bestandteile einfach zusam¬ mengemischt, es ist möglich, aber nicht notwendig, spezielle Bindemit¬ tel dabei einzusetzen. Bei der Herstellung von Kautabletten wird ein Guπ_nimaterial, beispielsweise Chiclegurrπii, Polyvinylester oder Poly¬ äthylen verwendet, also Materialien, wie sie auch für die Herstellung von Kaugurrmi Verwendung finden. Vorzugsweise wird aus Honig gewonnener Zucker beigefügt. Bei der Darreichungsform Kautablette wird ein sehr lang anhaltender Effekt erzielt, die einzelnen Wirkstoffe werden gün- stig und über die längere Kauzeit aufgeschlossen und entfalten daher im erwünschten Umfang ihre Wirkung.The plant constituents are simply mixed together during production; it is possible, but not necessary, to use special binders. A gum material, for example chicle gurriii, polyvinyl ester or polyethylene, is used in the manufacture of chewable tablets, that is to say materials such as are also used for the production of chewing gums. Sugar obtained from honey is preferably added. The chewable tablet formulation has a very long-lasting effect; the individual active ingredients are stig and open to the longer chewing time and therefore develop their effect to the desired extent.
Stattdessen kann auch ein Tee bereitet werden. Die Zubereitung erfolgt dabei wie bei einer Teebereitung mit normalen Teeblättern. Heißes Wasser wird in eine Tasse über mindestens eine Tablette des erfindungs- gemäßen Pha____a.zeut__kums gegossen, man läßt die Zubereitung einige Mi¬ nuten ziehen und trinkt sie, solange sie noch heiß sind.A tea can also be prepared instead. The preparation takes place like with a tea preparation with normal tea leaves. Hot water is poured into a cup over at least one tablet of the pha ____ a.zeut__kums according to the invention, the preparation is allowed to stand for a few minutes and is drunk while it is still hot.
Bei einem Gewicht einer Einzeltablette von 0,5 Gramm werden als Normal¬ dosis dreimal eine Tablette pro Tag empfohlen, die mit etwas Wasser eingenαπmen werden. Bei starken Rauchern ist es empfehlenswert, die Dosis zu verdoppeln. Die Tabletten werden mit den Mahlzeiten genαπrien, sie können vor, während oder nach Mahlzeiten eingenαrmen werden.With a weight of a single tablet of 0.5 grams, three tablets per day are recommended as a normal dose, which are taken with a little water. For heavy smokers, it is recommended to double the dose. The tablets are taken with meals, they can be taken before, during or after meals.
Die Behandlung sollte so lange durchgeführt werden, bis eine Wirkung spürbar ist, sie sollte aber nicht über mehr als fünf Tage erfolgen. Wenn nach dieser Zeit noch keine Wirkung, also keine Abneigung gegen Rauch und Rauchen, festgestellt wird, wird empfohlen, zwei bis drei Tage zu pausieren und dann erneut eine fünftätige Kur anzuschließen.The treatment should be continued until an effect is felt, but should not be given for more than five days. If after this time no effect, i.e. no aversion to smoking and smoking, is found, it is recommended to pause for two to three days and then to start a five-day course again.
Als wirksame chemische Bestandteile dieser Pflanzen für den Effekt gegen das Rauchen werden angesehen:The effective chemical components of these plants for the anti-smoking effect are considered:
Nödakenin im Peucedanum, Gentioside im Enzian (Gentiana) , Cimitin der Ci icifuga, Saponine und A-Spinasterol im Bupleurum. Nödakenin in the Peucedanum, Gentioside in the Gentian (Gentiana), Cimitin in the Ci icifuga, Saponine and A-Spinasterol in the Bupleurum.

Claims

Bezeichnung: Mittel gegen das RauchenA n s p r ü c h e Name: Remedy for smoking claims
1. Mittel gegen das Rauchen mit biochemischer Wirkung, zusamriengesetzt aus den folgenden, nicht giftigen, pflanzlichen Bestandteilen: Radix bupleuri, Radix peucedani, Rhizoma cimicifugae und Tubera pinelliae.1. Anti-smoking agent with a biochemical effect, composed of the following non-toxic, herbal ingredients: Radix bupleuri, Radix peucedani, Rhizoma cimicifugae and Tubera pinelliae.
2. Mittel nach Anspruch 1, dadurch gekennzeichnet, daß es zusätzlich Rhizcma phragmites enthalt.2. Composition according to claim 1, characterized in that it additionally contains Rhizcma phragmites.
3. Mittel nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß es zu¬ sätzlich Gentiana barbata (Enzian) und/oder Liquiritiae (bzw. Glycyrrhize) aufweist, wobei Liquiritiae ersetzt werden kann durch Robiniae pseudoacaciae.3. Composition according to claim 1 or 2, characterized in that it additionally has Gentiana barbata (gentian) and / or Liquiritiae (or Glycyrrhize), Liquiritiae can be replaced by Robiniae pseudoacaciae.
4. Mittel nach Anspruch 2, dadurch gekennzeichnet, daß die Bestandteile im folgenden, relativen Gewichtsverhältnis vorliegen:4. Composition according to claim 2, characterized in that the components are present in the following relative weight ratio:
Radix bupleuri 25 %, Radix peucedani 20 %, Rhizoma cimicifugae 25 %, Tubera pinelliae 20 % und Rhizcma phragmites 10 %.Radix bupleuri 25%, Radix peucedani 20%, Rhizoma cimicifugae 25%, Tubera pinelliae 20% and Rhizcma phragmites 10%.
5. Mittel nach Anspruch 3, dadurch gekennzeichnet, daß die Bestandteile im folgenden, relativen Gewichtsverhältnis vorliegen:5. Composition according to claim 3, characterized in that the components are present in the following relative weight ratio:
Peucedanum praeruptorum aus der Familie der Ranunculaceae 30 %, Gentiana barbata aus der Familie der Gentianaciae 24 %, Cimicifugae foetida aus der Familie der Ranunculaceae 12 %, Liquiritiae aus der Familie der Leguminosae oder Robiniae pseudoacaciae aus der Familie der Leguminosae 4 %, Bupleurum falcatum aus der Familie der Umbelli¬ ferae 12 % und Pinellia ternata aus der Familie der Araceae 18 %.Peucedanum praeruptorum from the Ranunculaceae family 30%, Gentiana barbata from the Gentianaciae family 24%, Cimicifugae foetida from the Ranunculaceae family 12%, Liquiritiae from the Leguminosae family or Robiniae pseudoacaciae from the Leguminupurum family 4% the family of the Umbelli¬ ferae 12% and Pinellia ternata from the family of the Araceae 18%.
6. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß die Bestandteile trocken und gegebenenfalls mit Bindemittel zu einer Tablette verpreßt werden. 6. Composition according to one of claims 1 to 5, characterized in that the constituents are pressed dry and optionally with a binder to form a tablet.
7. Mittel nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, daß die Bestandteile jeweils für sich mit Wasser aufgeschlossen werden, insbesondere durch Kochen, und daß aus der dabei erhaltenen wässri- gen Lösung eine Tablette, insbesondere in Form einer Kautablette, 'gefertigt wird.7. Composition according to one of claims 1 to 6, characterized in that the components are open to each with water, in particular by cooking, and that manufactured from the thus obtained gene wässri- solution, a tablet, particularly in the form of a chewable tablet, ' becomes.
8. Mittel nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, daß zu den Bestandteilen ein Kaugurr_rtibasismaterial wie Chiclegurπmi, Polyvinylester oder Polyäthylen hinzugefügt wird.8. Composition according to one of claims 1 to 7, characterized in that a Kaugurr_rtibasismaterial such as Chiclegurπmi, polyvinyl ester or polyethylene is added to the components.
9. Verwendung einer Mischung aus den folgenden pflanzlichen Bestandtei¬ len:9. Use of a mixture of the following herbal ingredients:
Radix bupleuri, Radix peucedani, Rhizcma cimicifugae und Tubera pinelliae als Mittel gegen das Rauchen.Radix bupleuri, Radix peucedani, Rhizcma cimicifugae and Tubera pinelliae as anti-smoking agents.
EP88901252A 1987-01-15 1988-01-15 Anti-smoking agent Withdrawn EP0341261A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3700982 1987-01-15
DE3700982 1987-01-15

Publications (1)

Publication Number Publication Date
EP0341261A1 true EP0341261A1 (en) 1989-11-15

Family

ID=6318861

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88901252A Withdrawn EP0341261A1 (en) 1987-01-15 1988-01-15 Anti-smoking agent

Country Status (4)

Country Link
US (1) US5130132A (en)
EP (1) EP0341261A1 (en)
JP (1) JPH03502092A (en)
WO (1) WO1988005305A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5592956A (en) * 1995-07-03 1997-01-14 Herbs For Health, Inc. Composition and method for inhibiting the desire for tobacco
KR100352030B1 (en) * 2002-01-10 2002-09-11 Orion Corp Gum composition for removing nicotine
BRPI0415741B1 (en) 2003-11-07 2013-07-23 tobacco compositions and methods of manufacturing a tobacco composition
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US8506936B2 (en) * 2008-11-25 2013-08-13 Watson Laboratories, Inc. Stabilized nicotine chewing gum

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2600700A (en) * 1949-03-08 1952-06-17 Colburn J Smith Composition for alleviation of the tobacco habit
US3011944A (en) * 1956-07-21 1961-12-05 Zh Nagao Kenkyusho Composition for eliminating toxic effects of nicotine and method of using same
BE668319A (en) * 1964-08-28
ES412146A1 (en) * 1972-03-11 1976-01-01 Pfizer Procedure for obtaining compositions to reduce tobacco's habit. (Machine-translation by Google Translate, not legally binding)
FR2375860A1 (en) * 1977-01-03 1978-07-28 Janssens Raymond Anti-smoking compsns. for oral administration - contain a substance to mask tobacco flavour and one to deaden the taste
JPH0641416B2 (en) * 1985-07-17 1994-06-01 保彦 小島 Method for producing bioactive substance of plant origin and composition containing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8805305A1 *

Also Published As

Publication number Publication date
JPH03502092A (en) 1991-05-16
US5130132A (en) 1992-07-14
WO1988005305A1 (en) 1988-07-28

Similar Documents

Publication Publication Date Title
DE69012823T2 (en) TOOLS TO ADJUST SMOKING OR USE IN NON-SMOKING AREAS.
Joshi Medicinal plants
DE60224832T2 (en) TOBACCO AND / OR TOBACCO IN COMBINATION WITH TOBACCO SUBSTITUTE COMPOSITION FOR USE AS A BUTCH IN THE MOUTH VALVE
CH658594A5 (en) MEDICINAL PRODUCT WITH ANTINICOTINE EFFECT AND METHOD FOR THE PRODUCTION THEREOF.
EP2862454B1 (en) Liquid composition for an electronic cigarette
DE69835280T2 (en) HEALTHY CIGARETTE
Crellin et al. Herbal medicine past and present
DE60202477T2 (en) DEVICE FOR ADMINISTERING A SUBSTANCE
DE602005005088T2 (en) SMOKING CIGARETTE
DE3705151A1 (en) WARTS
EP1977757B1 (en) Lozenge comprising Pelargonium in combination with Plantago
DE102008015101A1 (en) Chewing composition and its use
AT501560A1 (en) USE OF HERB CIGARETTES
DE69221635T2 (en) NEW TOBACCO REPLACEMENTS
ion Center A review of the properties and clinical effects of ginseng
Puri Vegetable aphrodisiacs of India
US6497234B1 (en) Herbal composition as a substitute for tobacco
EP0341261A1 (en) Anti-smoking agent
Blair Botanic drugs, their materia medica, pharmacology and therapeutics
Morion Plant products and occupational materials ingested by esophageal cancer victims in South Carolina
Cushny A Textbook of pharmacology and therapeutics, or, the Action of drugs in health and disease
CN107485673A (en) Liquid for stopping smoking using Cortex Magnoliae Officinalis tribulus terrestris etc. or its extraction component as main formula
Usman Poisonous Herbal Plants: NA
EP0450253B1 (en) Means for breaking the habitual use of tobacco
Marles The ethnopharmacology of the lowland Quichua of eastern Ecuador

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE FR GB LI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19910801